Compare Repligen Corporation Common Stock (RGEN) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SOLAI Limited — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Repligen Corporation Common Stock is far larger — about 12.9× SOLAI Limited's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SOLAI Limited for 42 Days on average.
| RGEN | SLAI | |
|---|---|---|
Market Cap | $11.31B | $880.09M |
Volume | 1,216,919 | 122,720 |
Sector | Health | Technology |
52-Week High | $194.57 | $21.63 |
52-Week Low | $102.87 | $2.74 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.20B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SOLAI Limited (SLAI) trades at $3.72 with no recent price movement, showing a mixed technical picture despite a bullish signal from indicators. The company faces severe financial distress with negative gross and net income margins, though it recently beat Q2 2025 EPS expectations. Recent developments include an extraordinary general meeting and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial execution and regulatory risks. While technical indicators suggest potential upside, fundamental weaknesses and delisting proceedings present clear downside risks. Investors should approach with caution given the company's negative profitability and ongoing corporate challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
